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ABSTRACT
Objective: To investigate the safety and efficacy of
QMF149, a once-daily, fixed-dose combination of the
long-acting β2-agonist (LABA) indacaterol maleate and
inhaled corticosteroid (ICS) mometasone furoate (MF)
for the treatment of persistent asthma. The hypothesis
was that QMF149 would not increase the risk of
serious asthma exacerbations.
Setting: 174 research centres in nine countries.
Participants: 1519 adolescents and adults with
persistent asthma who were treated or qualified for
treatment with combination LABA/ICS were
randomised, and 1508 were included in the intention-
to-treat analysis.
Intervention: Patients were randomised to QMF149
(indacaterol maleate 500 µg/MF 400 µg) or MF
(400 µg) once daily via Twisthaler inhalation device in
a double-blind, parallel-group study for 6–21 months.
Primary and secondary outcome measures: The
primary end point was time to first serious asthma
exacerbation (resulting in hospitalisation, intubation or
death). The key secondary end point was annual rate of
exacerbations requiring systemic corticosteroids.
Results: Treatment with QMF149 resulted in no
significant difference in time to first serious
exacerbation compared to MF (2 (0.3%) vs 6 events
(0.8%); difference −0.52 percentage point; 95% CI
−1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to
1.54, p=0.151). QMF149 significantly reduced the
annual rate of exacerbations requiring systemic
corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90,
p=0.005). Proportions of patients experiencing adverse
events were similar across groups (74.0% in the
QMF149 group and 73.4% in the MF group). Serious
adverse events occurred in 4% and 5.8% of patients in
the QMF149 and MF groups, respectively.
Conclusions: No significant difference was observed
in the primary outcome of time to first serious asthma
exacerbation in patients treated with QMF149
compared with patients treated with MF. Long-term
treatment with QMF149 once daily had a favourable
safety/efficacy profile in adolescent and adult patients
with persistent asthma.
Trial registration number: ClinicalTrials.gov;
NCT00941798.
INTRODUCTION
Inhaled corticosteroids (ICS) are the corner-
stone of therapy in persistent asthma in adoles-
cents and adults. However, in patients with
moderate-to-severe disease, the addition of a
long-acting β2-agonist (LABA) may be
required to achieve asthma control.1 2 This
concomitant use should be prescribed in the
form of a combination LABA/ICS single
inhaler product, as the use of separate inhalers
is likely to result in LABA monotherapy during
Strengths and limitations of this study
▪ This randomised controlled trial provides com-
prehensive data on the efficacy and safety of
QMF149, a once-daily, fixed dose combination of
the inhaled corticosteroid (ICS) mometasone
furoate (MF) and the long-acting β2-agonist
(LABA) indacaterol for the treatment of asthma.
▪ QMF149 had a favourable efficacy/safety profile,
reducing the rate of severe exacerbations requir-
ing systemic corticosteroids by 29%, compared
with MF therapy.
▪ Study findings may be generalised as the dose
of indacaterol 500 µg/MF 400 µg delivered via
the Twisthaler device is expected to be clinically
comparable to the dose of indacaterol 150 µg/MF
160 µg delivered via the Breezhaler device, which
will be the device used for QMF149 in phase III.
▪ The study was limited by the low rate of serious
exacerbations, resulting in insufficient power to
detect differences between treatment regimens.
▪ These findings are relevant to the issue of ICS/
LABA safety in asthma.
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periods of ICS non-adherence.3 This is important as LABA
monotherapy may be associated with an increased risk of
mortality in patients with unstable asthma.4
Combination LABA/ICS therapy also has the advan-
tage of improving compliance with ICS therapy,5 6 which
has the potential to reduce the risk of death due to the
dose-dependent relationship between ICS use and
asthma mortality.7 Existing twice-daily, fixed-dose combi-
nations of LABA/ICS have demonstrated efficacy in ran-
domised controlled trials.8 9 To date there is no evidence
to suggest an increase in risk of life-threatening attacks or
death from asthma with combination LABA/ICS
therapy.10 11 However, in view of a potential risk due to
LABA monotherapy, highlighted by the SMART study,12
and by systematic reviews4 including a meta-analysis con-
ducted by the US Food and Drug Administration
(FDA),13 it has been proposed that studies should be con-
ducted that specifically assess this risk with currently avail-
able and novel LABA/ICS products.14
QMF149 is a once-daily fixed-dose combination of the
LABA indacaterol maleate and the ICS mometasone
furoate (MF), which have both demonstrated 24 h
duration of action as monotherapies.15–18 QMF149 is
under development for the treatment of asthma and
chronic obstructive pulmonary disease. Increased dosing
frequency has been found to affect medication
compliance;19 therefore, the convenience of once-daily
QMF149 may help to improve treatment outcomes.
This phase II safety study was designed to investigate
the impact of QMF149 compared with MF on serious
outcomes of asthma-related death, intubation or hospi-
talisation14 in adolescent and adult patients with asthma.
As this composite outcome variable represents safety and
efficacy, it has allowed an assessment of the safety/effi-
cacy profile of QMF149 in adolescent and adult asthma.
QMF149 and MF were delivered via the Twisthaler inhal-
ation device, which is the current marketed device for
MF (Asmanex Twisthaler inhalation powder (Merck
Sharp & Dohme Corp; New Jersey, USA). However, as it
has been demonstrated that the Breezhaler device, a
single-dose dry powder inhaler, facilitates achievement
of comparable clinical effect at lower doses of indaca-
terol and MF (150 µg/160 µg compared with 500 µg/
400 µg via Twisthaler device20–22), the future develop-
ment of QMF149 will be via the Breezhaler inhalation
device.
METHODS
This was a randomised, double-blind, multicentre,
parallel-group study conducted between July 2009 and
May 2011. Investigators are listed in the online
supplementary appendix section 1. All patients discon-
tinued regular asthma maintenance therapy after
giving informed consent and were switched to
open-label MF 400 µg once daily for the run-in period
(21–28 days).
Randomisation and masking
Eligible patients were randomised in a 1:1 ratio to
receive once-daily QMF149 (indacaterol maleate
500 µg/MF 400 µg) or MF (400 µg) via Twisthaler inhal-
ation device, in the evening. Randomisation numbers
were generated using a procedure that ensured assign-
ment was unbiased and concealed from patients and
investigators: a patient randomisation list was produced
by an interactive voice response system (IVRS; Oracle
America Inc, Redwood City, California, USA) using a
validated system that automated the random assignment
of patient numbers to randomisation numbers. These
randomisation numbers were linked to the different
treatment groups, which in turn were linked to medica-
tion numbers. A separate medication randomisation list
was produced by or under the responsibility of Novartis
Drug Supply Management using a validated system that
automated the random assignment of medication
numbers to medication packs containing each of the
study drugs. Randomisation was stratified by the pres-
ence or absence of the following demographic and base-
line characteristics:
1. Patients who had an asthma-related hospitalisation
within the 12 months prior to randomisation.
2. Patients who had experienced asthma worsening(s)
that required either an emergency room visit with sys-
temic corticosteroid, or two or more courses of sys-
temic corticosteroids for asthma worsening during
the 12 months prior to randomisation.
3. African American patients or patients of black
African descent.
The study was completed per protocol when the first
patient had been in the study for 21 months and/or the
last patient for ≥6 months. The study was conducted
according to the World Medical Association’s Declaration
of Helsinki and approvals from institutional review
boards and/or ethics committees were obtained for each
investigator site.
Patients
This study enrolled patients aged 12–70 years, with a
documented diagnosis of persistent asthma for
≥6 months; a prebronchodilator forced expiratory
volume in 1 s (FEV1) ≥50% of predicted normal and a
post-short-acting β2-agonist (SABA) increase in FEV1 of
≥12% (and ≥200 mL) at the screening visit (3–4 weeks
prior to randomisation) or who had documented revers-
ibility within the previous 12 months; who were treated
or qualified for treatment with a LABA/ICS combin-
ation15 and had used an ICS for ≥2 months prior to
study start. No exacerbation history eligibility criteria
were specified. Full inclusion and exclusion criteria are
listed in the online supplementary appendix section 3.
Outcome measures
The primary end point was time to first serious asthma
exacerbation (resulting in hospitalisation, intubation or
death). Details of event adjudication and data monitoring
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procedures are provided in the online supplementary
appendix sections 4 and 5, respectively.
The key secondary end point was cumulative incidence
of serious asthma exacerbations. Other secondary end
points included time to first asthma exacerbation and
rate of exacerbations requiring systemic corticosteroids,
change from baseline in trough FEV1, e-diary data (peak
expiratory flow, rescue medication use, asthma scores),
and asthma control, assessed by overall Asthma Control
Questionnaire (ACQ-7) score.20 Exploratory end points
included impact on productivity and activity, as measured
by the Work Productivity and Activity Impairment
(WPAI-Asthma) questionnaire,23 and Euro Quality of
Life-5D Questionnaire (EQ-5D).24 All adverse events
(AEs) were recorded, including details of severity and
relationship to the study drug. Compliance was assessed
by counting remaining doses in each study device.
Data Monitoring Committee and interim analysis
An independent Data Monitoring Committee (DMC)
was formed to monitor asthma-related events on behalf
of study participants and investigators. The DMC
planned to meet every 6 months to review safety data,
with an additional event driven review to conduct
interim analysis when 10 serious asthma exacerbation
events had been accumulated and adjudicated.
One interim analysis was performed and a DMC
meeting was held on 31 August 2010 where the DMC
reviewed semiblinded safety data. Additional information
can be found in the online supplementary appendix
section 5.
Statistical analysis
Detailed statistical methods are provided in the online
supplementary appendix section 6.
It was estimated that 20 serious asthma exacerbations
were required to provide 80% power to detect a three-
fold increase in HR at α=0.05 (one sided) using nQuery
Advisor 7.0 (Statistical Solutions, Cork, Ireland). This
was based on assumptions that the annual rate of serious
asthma exacerbations would be 0.6% for MF25 and
between 1.8% and 2.4% for QMF149, following the FDA
meta-analysis, which found asthma-related events in the
range of 1.0–1.6% and estimated a risk difference of
2.80 per 1000 participants for patients receiving LABA
treatment compared with non-LABA treatment.13 The
total of 750 patients per arm was chosen as the average
of these two scenarios.
Time to the first serious exacerbation was analysed
using a Cox proportional hazards regression model
stratified by asthma-related hospitalisation in the last
12 months (no/yes), asthma worsening in the last
12 months (no/yes) and African-American patient (no/
yes), including terms for treatment and region. The
annualised rate of exacerbations was evaluated using a
negative binomial regression model. Other secondary
end points were analysed using a repeated measures ana-
lysis of covariance, based on longitudinal measurements,
which assumed data were missing at random. No missing
data imputation was performed. Analyses were per-
formed using two sided 95% CI and p values.
Efficacy analyses were performed on the full analysis
set (all randomised patients receiving at least one dose
of randomised study medication, analysed according to
randomised study medication). All safety parameters
were summarised on the safety set (all patients receiving
at least one dose of study medication, analysed accord-
ing to treatment actually received).
RESULTS
Patients
A total of 1519 patients were randomised to receive
treatment (QMF149=756; MF=763) (figure 1). The full
analysis set comprised 1508 patients. The median dur-
ation of study treatment was 405 and 406 days in the
QMF149 and MF treatment groups, respectively. Similar
proportions of patients discontinued prematurely in
both groups (QMF149=194 (25.7%) and MF=185
(24.2%)). The most common reason for early discon-
tinuation of study treatment across both treatment
groups was withdrawal of consent (9.6%). A higher pro-
portion of patients in the QMF149 group withdrew due
to AEs (5.7%) compared with the MF treatment group
(3.0%), but a greater proportion of patients (2.2%) in
the MF group withdrew due to unsatisfactory therapeutic
effect of study treatment compared with the QMF149
treatment group (1.3%; figure 1).
Baseline demographics and clinical characteristics
were well balanced across groups (table 1). The study
population presented with a mean baseline (pre-SABA)
FEV1 of approximately 75% predicted and reversibility
of approximately 22%. Similar proportions of patients
were compliant with study medication at the final study
visit (91% and 91.9% in the QMF149 and MF treatment
groups, respectively).
Serious asthma exacerbations
In total, eight patients (two QMF149 and six MF) experi-
enced a serious asthma exacerbation; none required
intubation or resulted in death. There were too few
events to estimate the time to first serious asthma exacer-
bation at most percentiles. The difference between
QMF149 and MF did not reach statistical significance
(HR=0.31; 95% CI 0.06 to 1.54, p=0.151 (table 2)). The
difference in the cumulative incidence of serious asthma
exacerbation between the QMF149 and MF treatment
groups was −0.52 percentage point (95% CI −1.25 to
0.21, p=0.160).
Asthma exacerbations requiring systemic corticosteroids
More patients in the MF group had an asthma exacerba-
tion requiring treatment with systemic corticosteroids
compared with the QMF149 group (22.5% and 16.6%,
respectively; difference 5.9 percentage points).
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QMF149 significantly reduced the risk in the time to
first exacerbation requiring systemic corticosteroids by
30% (HR=0.70; 95% CI 0.56 to 0.89, p=0.003; figure 2)
and the annual rate of exacerbations requiring systemic
corticosteroids by 29% (rate ratio=0.71; 95% CI 0.55 to
0.90, p=0.005) compared with MF.
Lung function
Trough FEV1 significantly improved during treatment
with QMF149 compared with MF at all study visits
(table 3). Improvements at week 4 were maintained over
68 weeks with treatment differences ranging from 0.10 L
(95% CI 0.05 to 0.15) to 0.14 L (0.11 to 0.18; p≤0.001 at
all visits). Compared with MF, QMF149 also resulted in
significantly (p≤0.001) greater improvements in forced
vital capacity (FVC) at each visit (day 1, weeks 4–68).
The adjusted mean treatment difference (QMF149–
MF) for changes from baseline in morning and evening
peak expiratory flow were statistically significant in
favour of QMF149 (adjusted mean difference 0.44 L/s
(95% CI 0.36 to 0.52) and 0.42 L/s (0.34 to 0.50),
respectively, both p≤0.001).
Asthma symptoms, rescue medication use and asthma
control
The percentage of days with no asthma symptoms was
significantly increased during treatment with QMF149
compared with MF (table 3). Adjusted mean treatment
differences during the morning, daytime and night-time
were 3.9% (95% CI 1.5 to 6.3), 7.7% (95% CI 4.5 to
10.9) and 6.3% of days (95% CI 3.4 to 9.2), respectively.
QMF149 also significantly increased the percentage of
days with no rescue medication use during daytime,
night-time and 24-h periods compared with MF.
Adjusted mean treatment differences ranged from 9.8%
Figure 1 Patient flow through
the study (CONSORT diagram).
*Patients could be allocated to
more than one group concerning
reason for exclusion.
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(95% CI 6.8 to 12.8) to 11.3% of days (8.1 to 14.4; all
p<0.001).
Asthma control, as assessed by ACQ-7 score, was signifi-
cantly improved with QMF149 compared with MF by week
4 and thereafter at each subsequent visit throughout the
treatment period (table 3). Adjusted mean treatment differ-
ences between QMF149 and MF ranged from −0.13 (−0.20
to −0.06) to −0.23 (−0.33 to −0.13; all p<0.001), with an
overall adjusted mean difference of −0.19 (−0.25 to −0.14;
p<0.001) in favour of QMF149. The overall changes from
baseline were −0.49 for QMF149 and −0.29 for MF.
Improvements from baseline in EQ-5D were similar in
the QMF149 and MF treatment groups. For WPAI-asthma,
change from baseline in the percentage of activity







Age (years) 42.4 (14.75) 42.3 (14.58) 42.3 (14.66)
Age group (years)
<18 31 (4.1%) 35 (4.6%) 66 (4.4%)
18–64 675 (90.1%) 682 (89.9%) 1357 (90.0%)
≥65 43 (5.7%) 42 (5.5%) 85 (5.6%)
Sex
Male 313 (41.8%) 310 (40.8%) 623 (41.3%)
Female 436 (58.2%) 449 (59.2%) 885 (58.7%)
Race
Caucasian 460 (61.4%) 474 (62.5%) 934 (61.9%)
Asian 142 (19.0%) 143 (18.8%) 285 (18.9%)
Black 58 (7.7%) 53 (7.0%) 111 (7.4%)
Other 89 (11.9%) 89 (11.7%) 178 (11.8%)
BMI (kg/m2) 27.4 (6.33) 27.5 (6.37) 27.5 (6.35)
Smoking history
Never smoked 631 (84.2) 635 (83.7) 1266 (84.0)
Ex-smoker 117 (15.6) 123 (16.2) 240 (15.9)
FEV1 before inhalation of SABA (L) 2.29 (0.773) 2.30 (0.755) 2.29 (0.764)
FEV1 before inhalation of SABA (% of predicted FEV1) 75.1 (15.86) 75.5 (15.28) 75.3 (15.56)
FEV1 reversibility (%) 21.6 (13.46) 21.8 (13.61) 21.7 (13.53)
Mean ACQ-7 score at baseline 1.7 1.7 1.7
Data are mean (SD) or n (%). Reversibility is the percentage increase of FEV1 after inhalation of SABA compared with FEV1 before inhalation
of SABA.
ACQ-7, Asthma Control Questionnaire; BMI, body mass index; FEV1, forced expiratory volume in 1 s; MF, mometasone furoate; SABA,
short-acting β2-agonist.





Patients with serious asthma exacerbation 2 (0.3%) 6 (0.8%)
Difference in cumulative incidences % (95% CI) −0.52 (−1.25 to 0.21)
p=0.160
Follow-up time, median months (range) 13.3 (0–19.6) 13.4 (0–20.3)
Event-free rates % (95% CI)
6 months 99.7 (98.8 to 99.9) 99.7 (98.9 to 99.9)
12 months 99.7 (98.8 to 99.9) 99.3 (98.2 to 99.7)
18 months 99.7 (98.8 to 99.9) 99.0 (97.6 to 99.5)
21 months – –
Cox regression analysis
HR QMF149/MF (95% CI) 0.31 (0.06 to 1.54)
p=0.151
Data are n (%) unless otherwise specified. Patients who did not experience a serious asthma exacerbation were censored at their last
follow-up date. Follow-up time=time from randomisation until the first serious asthma exacerbation or censoring. Event-free time rates were
calculated by the Kaplan Meier method. The Cox regression model included the terms for treatment and region, stratified by history of asthma
related hospitalisation in the past 12 months (yes/no), history of asthma worsening in the past 12 months (yes/no) and African-American
patient (yes/no). A HR <1 favours QMF149.
CI, confidence interval; MF, mometasone furoate; MR, mometasone.
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impairment during work caused by asthma was statistically
significantly reduced (improved) in the QMF149 treat-
ment group compared with the MF treatment group
overall (−1.5 (−2.7 to −0.2); p=0.022), at week 12 (−1.8
(−3.5 to −0.2); p=0.032) and at the final clinic visit (−2.2
(−4.2 to −0.3); p=0.026).
Figure 2 Kaplan–Meier plot of
time to first asthma exacerbation
requiring treatment with systemic
corticosteroids.
Table 3 Changes from baseline in trough FEV1 and ACQ-7 average score by visit, and asthma symptoms summarised
throughout the treatment period
QMF149 MF Treatment difference: QMF149–MF
Variable n (%) LS mean SE n (%) LS mean SE LS mean SE 95% CI
Change from baseline in trough FEV1 by visit (L)
Overall 727 (100) 0.07 0.023 746 (100) −0.05 0.023 0.12*** 0.014 (0.09 to 0.15)
Week 4 709 (97.5) 0.09 0.023 728 (97.6) −0.04 0.023 0.13*** 0.014 (0.10 to 0.16)
Week 12 681 (93.7) 0.08 0.024 693 (92.9) −0.02 0.024 0.11*** 0.016 (0.08 to 0.14)
Week 26 643 (88.4) 0.08 0.024 658 (88.2) −0.04 0.024 0.12*** 0.017 (0.08 to 0.15)
Week 52 431 (59.3) 0.07 0.025 443 (59.4) −0.07 0.025 0.14*** 0.018 (0.11 to 0.18)
Week 68 176 (24.2) 0.06 0.028 171 (22.9) −0.05 0.028 0.10*** 0.026 (0.05 to 0.15)
Final visit 674 (92.7) 0.06 0.025 699 (93.7) −0.07 0.024 0.12*** 0.018 (0.09 to 0.16)
Change from baseline in ACQ-7 score by visit
Overall 728 (100) −0.49 0.049 745 (100) −0.29 0.049 −0.19*** 0.028 (−0.25 to −0.14)
Week 4 709 (97.4) −0.35 0.049 734 (98.5) −0.15 0.049 −0.20*** 0.031 (−0.26 to −0.14)
Week 12 679 (93.3) −0.45 0.050 697 (93.6) −0.24 0.050 −0.21*** 0.034 (−0.28 to −0.15)
Week 26 648 (89.0) −0.50 0.051 660 (88.6) −0.38 0.051 −0.13*** 0.035 (−0.20 to −0.06)
Week 52 432 (59.3) −0.52 0.052 447 (60.0) −0.35 0.052 −0.17*** 0.038 (−0.24 to −0.10)
Week 68 178 (24.5) −0.55 0.056 173 (23.2) −0.32 0.057 −0.23*** 0.050 (−0.33 to −0.13)
Final visit 675 (92.7) −0.55 0.052 687 (92.2) −0.32 0.052 −0.22*** 0.040 (−0.30 to −0.14)
Percentage of days with no asthma symptoms during
Morning 730 22.3 2.17 746 18.4 2.17 3.9*** 1.20 (1.5 to 6.3)
Daytime 731 27.1 2.96 749 19.5 2.95 7.7*** 1.63 (4.5 to 10.9)
Night-time 730 23.6 2.69 746 17.3 2.68 6.3*** 1.49 (3.4 to 9.2)
***p≤0.001. The ACQ-7 score ranges from 0=good control of asthma to 6=very poor control of asthma.
ACQ-7, Asthma Control Questionnaire; FEV1, forced expiratory volume in 1 s; LS, least squares; MF, mometasone furoate; SE, standard error.
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Safety
The median number of days of exposure was 405 days in
the QMF149 group and 406 days in the MF group.
Serious AE (SAEs) occurred in 4.0% of patients in the
QMF149 group and 5.8% of patients in the MF group.
Asthma (defined as asthma worsening and/or asthma
exacerbation) was the most frequent SAE, reported by
two patients in the QMF group (0.3%) and nine patients
in the MF group (1.2%) (see online supplementary
table S1 and appendix section 7). The other most fre-
quently reported SAEs were pneumonia (none with
QMF149 and 4 (0.5%) with MF; confirmed by either
radiographic evidence or investigator examination) and
appendicitis (2 (0.3%) in each group). Seven patients
(0.9%) in both treatment groups discontinued treat-
ment because of an SAE. There was one death (in the
MF group) due to multiorgan failure following surgery
that was not treatment or asthma related.
The overall incidence of AEs was similar in both treat-
ment groups: 554 QMF149 patients (74%) and 557 MF
patients (73.4%) (see online supplementary table S2
and appendix section 7). Treatment-related AEs
(TRAEs) (as per investigator assessment) were reported
in 269 (35.9%) and 81 (10.7%) patients in the QMF149
and MF groups, respectively. The most frequently occur-
ring AEs (in >1% patients in either group) were asthma
and cough (see online supplementary table S3).
Overall, asthma was reported as an AE in 275 (36%)
patients in the MF group and 196 (26%) patients in the
QMF149 group, and as a TRAE in 21 (3%) and 13 (2%)
patients in the two groups, respectively. Cough was
reported overall as an AE in 266 (36%) patients in the
QMF149 group and in 64 (8%) patients in the MF
group, and as a TRAE in 238 (32%) and 32 (4%)
patients in the two groups, respectively.
DISCUSSION
This phase II study has shown a favourable safety/effi-
cacy profile for once-daily QMF149 in the treatment of
adolescents and adults with persistent asthma.
Compared with MF, treatment with QMF149 demon-
strated a trend towards reducing the risk of serious
asthma exacerbations, and a significant reduction of
29% in the annual rate of asthma exacerbations requir-
ing systemic corticosteroids. QMF149 also resulted in sig-
nificant improvements in lung function, asthma
symptoms and asthma control.
In this study, the HR for the risk of serious exacerba-
tions was numerically in favour of QMF149 but was not
significant (0.31; 95% CI 0.06 to 1.54, p=0.151). Based
on the Wolfe et al25 study and event rates in the FDA
LABA safety meta-analysis,13 it was predicted that the
sample size of 1500 patients would result in 20 serious
asthma exacerbations during this study, thereby provid-
ing 80% power to detect a threefold increase in HR with
QMF149. The numbers of serious asthma exacerbations
were lower than predicted in the QMF149 treatment
group with a corresponding reduction in power and
wider CI. However, the low event rate may be seen as
indirect evidence that both treatments are effective in
the prevention of serious asthma events.
These findings are consistent with those from previous
studies of currently prescribed LABA/ICS products.10 11
To date, there has been no evidence that fixed-dose
combinations of salmeterol/fluticasone propionate11 or
formoterol/budesonide,10 both of which require twice-
daily administration, are associated with an increased
risk of serious asthma exacerbations leading to hospital
admission, intubation or death, compared with ICS
therapy. However, the interpretation relating to mortality
is limited to some extent by the low statistical power of
the available studies for this outcome.
The primary outcome variable was time to first serious
asthma exacerbation resulting in hospital admission,
intubation or mortality, based on that mandated by the
FDA in a series of related randomised controlled trials
of LABA/ICS products currently used in the treatment
of asthma.14 The use of this outcome variable recognises
that it is difficult to assess mortality alone as a primary
outcome variable in clinical trials of asthma, largely
owing to its rarity, even in patients with moderate-
to-severe disease. This is well illustrated by an independ-
ent analysis of a salmeterol database, in which there
were no deaths or intubations among more than 22 000
subjects in the 63 studies of salmeterol/fluticasone pro-
pionate.11 The outcome’s rationale is also based on the
observation that an increased risk in hospital admission
tracks with mortality risk in studies of LABA therapy
and, as a result, hospital admissions can be considered
an acceptable surrogate for risk of mortality.11
A further clinically important outcome was the time to
first asthma exacerbation requiring treatment with sys-
temic corticosteroids. There was a clear difference
between treatment groups for this end point with 17%
of QMF149 patients experiencing exacerbations requir-
ing systemic corticosteroids compared with 23% receiv-
ing MF. Overall, there was a 30% reduction in risk in the
time to first exacerbation requiring treatment with sys-
temic corticosteroids in patients receiving QMF149 com-
pared with MF. Similarly, asthma reported as an AE
(defined as asthma worsening and/or asthma exacerba-
tion) occurred more frequently in the MF treatment
group (36%) compared with the QMF149 treatment
group (26%).
Lung function, assessed as change from baseline in
trough FEV1, showed statistically significant treatment
differences in favour of QMF149, ranging between
0.10 L and 0.14 L throughout the study period. These
differences between two active treatments are within the
range considered to be clinically relevant for treatments
compared with placebo.26 27 This demonstrated persist-
ence of efficacy during the treatment period, with no
evidence of bronchodilator tolerance.
Other secondary efficacy variables such as symptom-
free days (morning, daytime and night-time) and rescue
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medication use showed statistically significant treatment
differences in favour of QMF149 throughout the study.
Such improvements over MF are consistent with those
demonstrated with other LABA/ICS combination ther-
apies compared with ICS used as monotherapy.8 9
Improvements in asthma control as measured with the
ACQ-7 were consistently statistically significantly higher
with QMF149 compared with MF. QMF149 achieved an
overall improvement of −0.49 from baseline, which is
considered clinically relevant.28 Clinically relevant
improvements were not demonstrated in the MF treat-
ment group.
QMF149 is comprised of two molecules with established
efficacy and safety profiles. The indacaterol maleate dose,
selected from dose ranging studies in asthma, results in
rapid onset bronchodilation that is maintained for at least
24 h.15 21 Once-daily dosing is established as an effective
regimen for MF.22 29 The use of a once-daily evening dose
of 400 µg was based on a clinical trial programme, which
demonstrated that 400 µg is near the top of the thera-
peutic dose-response curve in persistent asthma,22 that
once-daily was as efficacious as twice-daily dosing29 and
that evening may be superior to morning dosing.30 The
choice of MF as the ICS component was also based on its
favourable efficacy/safety profile.31 Thus, indacaterol
maleate and MF have established efficacy when used once
daily in the evening. It is possible that once-daily dosing of
LABA/ICS products may lead to improved compliance19
and, thereby, efficacy compared with twice-daily regimens;
however, this issue requires further study.
While the assessment of safety was based primarily on
serious asthma exacerbations and exacerbations requir-
ing systemic corticosteroids, the trial was of sufficient
duration to assess the overall safety profile of QMF149,
and AEs were recorded rigorously throughout the study.
In general, the incidence of AEs was similar across the
treatment groups with the exception of asthma and
cough. The higher incidence of cough in the QMF149
treatment group was likely due to the use of the maleate
salt of indacaterol in this study. A study comparing the
maleate with the acetate salt of indacaterol showed that
indacaterol acetate is associated with a lower incidence
of cough with no impact on the efficacy, safety, or toler-
ability of treatment (Novartis data on file, 2012). Future
studies of QMF149 will use indacaterol acetate rather
than indacaterol maleate.
In addition, based on systemic exposure comparisons
for indacaterol32 33 and MF,34 QMF149 will be delivered
via the Breezhaler device in future development, rather
than the Twisthaler device marketed for MF. QMF149
delivered via the Breezhaler device is currently being
evaluated as a fixed-dose combination, where a dose of
indacaterol acetate 150 µg/MF 160 µg is comparable to
indacaterol maleate 500 µg/MF 400 µg delivered via the
Twisthaler device. Thus, since QMF149 150 µg/160 μg via
the Breezhaler device with the acetate salt is expected to
be clinically comparable to QMF149 500 µg/400 μg with
the maleate salt via the Twisthaler device, the current
study provides important data to support the safety and
efficacy profile of the final product.
In conclusion, this study has shown a favourable
safety/efficacy profile of QMF149 in the treatment of
persistent asthma. Improvements in lung function,
symptom control and rescue medication use, and reduc-
tions in risk in time to first exacerbation requiring sys-
temic corticosteroids, and in the annual rate of asthma
exacerbations requiring systemic corticosteroids, were all
significantly in favour of treatment with QMF149.
QMF149 treatment was also associated with a numerical,
but not significant, reduction in the risk of serious
asthma exacerbations. QMF149 may be a useful treat-
ment option in adolescents and adults with asthma who
qualify for treatment with a LABA/ICS combination.
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